Identifying blood markers for early diagnosis of transplant-related complications
Official title: Screening and Identification of Plasma Biomarkers for Early Diagnosis of Transplant-associated Thrombotic Microangiopathy Based on Proteomics and Metabolomics Techniques
Run by Institute of Hematology & Blood Diseases Hospital, China · NCT06102694 · Data updated 2026-11-12
This study is trying to find blood markers that can help doctors spot early signs of a serious complication called TA-TMA in patients who have had a stem cell transplant.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 14 Years to 70 Years |
| Sex | All |
| Enrollment | 500 (estimated) |
| Sponsor | Institute of Hematology & Blood Diseases Hospital, China Academic / other |
| Locations | 1 site (Tianjin) |
| Status | Recruiting |
| Started | November 16, 2023 |
| Main results expected | September 2025 |
| Study ends | December 2025 |
| Registry record updated | August 6, 2025 |
| Trial ID | NCT06102694 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are adults aged 18 and older who have been diagnosed with a hematologic disease and are undergoing allogeneic hematopoietic stem cell transplantation.
✕Probably not a fit
Patients with a history of prior allogeneic hematopoietic stem cell transplantation or those with severe organ dysfunction may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This clinical trial aims to identify plasma biomarkers that can accurately diagnose and predict transplant-associated thrombotic microangiopathy (TA-TMA) in patients undergoing hematopoietic stem cell transplantation. The study will collect and analyze blood and urine samples from participants at regular intervals post-transplantation to explore the relationship between specific biomarkers and the occurrence of TA-TMA. By utilizing advanced proteomics and metabolomics techniques, the researchers hope to establish a cohort that can lead to the discovery of new early warning biomarkers for TA-TMA, addressing a significant gap in current diagnostic practices.
Why it matters
Potential benefit: If successful, this study could lead to earlier diagnosis and improved management of TA-TMA, potentially reducing mortality rates associated with this condition.
How similar studies have gone: While there is a lack of large-scale prospective studies specifically on TA-TMA, the use of multi-omics technologies for biomarker discovery has shown promise in other areas of medical research.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * 1\. Diagnosis of a hematologic disease (e.g., leukemia, myelodysplastic syndromes,lymphoma) confirmed by histology or other appropriate diagnostic methods. * 2\. undergoing allo-HSCT * 3\. Age 14 years or older * 4.Informed consent must be signed before the start of the study. For participants aged 18 and above, the informed consent should be signed by the patient or their immediate family member. Considering the patient's condition, if it is not favorable for the patient to sign, the informed consent may be signed by a legal guardian or immediate family member of the patient. Exclusion Criteria: * 1\. Missing or lost follow-up of key clinical data * 2\. failure to collect plasma samples at specific time points after transplantation * 3\. Plasma sample collection time later than the onset date of TMA * 4\. TMA occurrence time later than 180 days after transplantation
Where it's running
-
Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences
Tianjin, China Recruiting
Study contacts
- Principal investigator: Erlie Jiang — Chinese Academy of Medical Sciences
- Study coordinator: Wenbin Cao
- Email: caowenbin@ihcams.ac.cn
- Phone: 15620820820
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Evaluating narsoplimab for treating TMA in children after stem cell transplants
This study is testing a new treatment called narsoplimab to see if it can help children who are at high risk for blood vessel problems after getting stem cell transplants.
-
Population PK-guided ATG Dosing in Haploidentical Stem Cell Transplant
This trial tests a population PK-guided ATG dosing strategy in people undergoing haploidentical hematopoietic stem cell transplantation to see if it improves outcomes.
-
Population PK-guided ATG Dosing in Haplo-HSCT
This study tests a population PK-guided dosing strategy for anti-thymocyte globulin (ATG) in adults and adolescents undergoing haploidentical stem cell transplantation to see if it can reduce GVHD while keeping relapse risk acceptable.
-
Low-dose liposomal amphotericin B to prevent invasive fungal infections in neutropenic children
This study tests whether giving a fixed low dose of liposomal amphotericin B can prevent invasive fungal infections in children aged 3–17 who are severely neutropenic after hematopoietic stem cell transplantation or similar high-risk conditions.
-
Role of Interferon and Complement in Second-ary Thrombotic Microangiopathy
This study tests whether interferon levels relate to the development of TA-TMA in people who have had a transplant or related conditions.
-
Personalized ATG dosing in unrelated donor stem cell transplants
This trial tests whether tailoring anti-thymocyte globulin dosing works better than standard fixed dosing in adults and adolescents receiving unrelated donor stem cell transplants.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.